PURPOSE: Myeloperoxidase (MPO) generates reactive oxygen species and also activates xenobiotics. In a rigorous clinical trial (Southwest Oncology Group SWOG-8897), we examined relationships between genotypes and disease-free survival (DFS) among women treated for breast cancer, as well as those who did not receive adjuvant chemotherapy. PATIENTS AND METHODS: Patients were assigned to risk groups according to standard prognostic features; the low-risk group (n = 753 genotyped) received follow-up only, and the high-risk group (n = 401 genotyped) was randomly assigned to adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) or cyclophosphamide, doxorubicin, and fluorouracil (CAF), with or without tamoxifen. DNA from archived normal lymph node tissue was genotyped, and Cox proportional hazard models were used to calculate DFS associated with MPO genotypes. RESULTS: Among women in the treatment arm, those with MPO G alleles had more than a two-fold reduction in hazard of recurrence (adjusted hazard ratio [HR] for GA genotypes, 0.51; 95% CI, 0.21 to 0.99; HR for GG genotypes, 0.41; 95% CI, 0.21 to 0.77). Effects were greatest among women who were further randomly assigned to tamoxifen (HR for GA genotypes, 0.28; 95% CI, 0.12 to 0.69; HR for GG genotypes, 0.19; 95% CI, 0.08 to 0.45). There were no significant associations between genotypes and DFS among women in the untreated arm, and relationships between genotypes and DFS did not differ by CAF or CMF. CONCLUSION: These results, observed in two independent study populations, indicate that high-activity MPO genotypes are associated with better survival among women receiving cyclophosphamide-containing therapy, particularly when followed by tamoxifen therapy. MPO can be inhibited and/or upregulated by commonly used drugs; thus, our findings merit further investigation for optimization of therapeutics for breast cancer.
RCT Entities:
PURPOSE:Myeloperoxidase (MPO) generates reactive oxygen species and also activates xenobiotics. In a rigorous clinical trial (Southwest Oncology Group SWOG-8897), we examined relationships between genotypes and disease-free survival (DFS) among women treated for breast cancer, as well as those who did not receive adjuvant chemotherapy. PATIENTS AND METHODS: Patients were assigned to risk groups according to standard prognostic features; the low-risk group (n = 753 genotyped) received follow-up only, and the high-risk group (n = 401 genotyped) was randomly assigned to adjuvant cyclophosphamide, methotrexate, and fluorouracil (CMF) or cyclophosphamide, doxorubicin, and fluorouracil (CAF), with or without tamoxifen. DNA from archived normal lymph node tissue was genotyped, and Cox proportional hazard models were used to calculate DFS associated with MPO genotypes. RESULTS: Among women in the treatment arm, those with MPO G alleles had more than a two-fold reduction in hazard of recurrence (adjusted hazard ratio [HR] for GA genotypes, 0.51; 95% CI, 0.21 to 0.99; HR for GG genotypes, 0.41; 95% CI, 0.21 to 0.77). Effects were greatest among women who were further randomly assigned to tamoxifen (HR for GA genotypes, 0.28; 95% CI, 0.12 to 0.69; HR for GG genotypes, 0.19; 95% CI, 0.08 to 0.45). There were no significant associations between genotypes and DFS among women in the untreated arm, and relationships between genotypes and DFS did not differ by CAF or CMF. CONCLUSION: These results, observed in two independent study populations, indicate that high-activity MPO genotypes are associated with better survival among women receiving cyclophosphamide-containing therapy, particularly when followed by tamoxifen therapy. MPO can be inhibited and/or upregulated by commonly used drugs; thus, our findings merit further investigation for optimization of therapeutics for breast cancer.
Authors: Jiyoung Ahn; Marilie D Gammon; Regina M Santella; Mia M Gaudet; Julie A Britton; Susan L Teitelbaum; Mary Beth Terry; Alfred I Neugut; P David Josephy; Christine B Ambrosone Journal: Cancer Res Date: 2004-10-15 Impact factor: 12.701
Authors: Rob Michalides; Alexander Griekspoor; Astrid Balkenende; Desiree Verwoerd; Lennert Janssen; Kees Jalink; Arno Floore; Arno Velds; Laura van't Veer; Jacques Neefjes Journal: Cancer Cell Date: 2004-06 Impact factor: 31.743
Authors: Frederik J Van Schooten; Agnes W Boots; Ad M Knaapen; Roger W L Godschalk; Lou M Maas; Paul J A Borm; Marjolein Drent; Jan A Jacobs Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-05 Impact factor: 4.254
Authors: Heather L Gustafson; Song Yao; Bryan H Goldman; Kristy Lee; Catherine M Spier; Michael L LeBlanc; Lisa M Rimsza; James R Cerhan; Thomas M Habermann; Brian K Link; Matthew J Maurer; Susan L Slager; Daniel O Persky; Thomas P Miller; Richard I Fisher; Christine B Ambrosone; Margaret M Briehl Journal: Am J Hematol Date: 2014-04-12 Impact factor: 10.047
Authors: Song Yao; William E Barlow; Kathy S Albain; Ji-Yeob Choi; Hua Zhao; Robert B Livingston; Warren Davis; James M Rae; I-Tien Yeh; Laura F Hutchins; Peter M Ravdin; Silvana Martino; Alan P Lyss; C Kent Osborne; Martin Abeloff; Gabriel N Hortobagyi; Daniel F Hayes; Christine B Ambrosone Journal: Clin Cancer Res Date: 2010-12-15 Impact factor: 12.531
Authors: Song Yao; William E Barlow; Kathy S Albain; Ji-Yeob Choi; Hua Zhao; Robert B Livingston; Warren Davis; James M Rae; I-Tien Yeh; Laura F Hutchins; Peter M Ravdin; Silvana Martino; Alan P Lyss; C Kent Osborne; Martin D Abeloff; Gabriel N Hortobagyi; Daniel F Hayes; Christine B Ambrosone Journal: Breast Cancer Res Treat Date: 2010-03-23 Impact factor: 4.872
Authors: Dan Cacsire Castillo-Tong; Dietmar Pils; Georg Heinze; Ioana Braicu; Jalid Sehouli; Alexander Reinthaller; Eva Schuster; Andrea Wolf; Rafal Watrowski; Richard A Maki; Robert Zeillinger; Wanda F Reynolds Journal: Tumour Biol Date: 2013-07-27
Authors: Ji-Yeob Choi; William E Barlow; Kathy S Albain; Chi-Chen Hong; Javier G Blanco; Robert B Livingston; Warren Davis; James M Rae; I-Tien Yeh; Laura F Hutchins; Peter M Ravdin; Silvana Martino; Alan P Lyss; C Kent Osborne; Martin D Abeloff; Daniel F Hayes; Christine B Ambrosone Journal: Clin Cancer Res Date: 2009-08-11 Impact factor: 12.531
Authors: Joanne W Elena; Lois B Travis; Naoko I Simonds; Christine B Ambrosone; Rachel Ballard-Barbash; Smita Bhatia; James R Cerhan; Patricia Hartge; Rebecca S Heist; Lawrence H Kushi; Timothy L Lash; Lindsay M Morton; Kenan Onel; John P Pierce; Leslie L Robison; Julia H Rowland; Deborah Schrag; Thomas A Sellers; Daniela Seminara; Xiao Ou Shu; Nancy E Thomas; Cornelia M Ulrich; Andrew N Freedman Journal: J Natl Cancer Inst Date: 2012-11-28 Impact factor: 13.506
Authors: Navin Pinto; Sandi L Navarro; Christine Rimorin; Michelle Wurscher; Douglas S Hawkins; Jeannine S McCune Journal: Pediatr Blood Cancer Date: 2021-07-10 Impact factor: 3.167
Authors: Thais Helena Gasparoto; Carine Ervolino de Oliveira; Luisa Thomazini de Freitas; Claudia Ramos Pinheiro; Rodrigo Nalio Ramos; André Luis da Silva; Gustavo Pompermaier Garlet; João Santana da Silva; Ana Paula Campanelli Journal: J Inflamm (Lond) Date: 2012-11-23 Impact factor: 4.981